$846.33 general Payment -- Regeneron Pharmaceuticals to Dr. Melissa Reed
Regeneron Pharmaceuticals Pays $846.33 for Xarelto Education to Allergy & Immunology Specialist
This page provides a detailed analysis of a $846.33 general payment from Regeneron Pharmaceuticals to Dr. Melissa Reed. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $846.33 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Melissa Reed |
| NPI Number | 1601100320 |
| Physician Specialty | Allergy & Immunology |
| Location | Flint, MI |
| Date of Payment | 2025-12-25 |
| Related Drug/Device | Xarelto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $846.33 general payment to Melissa Reed, a Allergy & Immunology specialist in Flint, MI. The payment was associated with Xarelto. The payment of $846.33 to Dr. Melissa Reed for "Education" related to Xarelto by Regeneron Pharmaceuticals is a notable transaction. This payment occurred on December 25, 2025, indicating a potential holiday-season engagement. The specialty of Allergy & Immunology is listed, which may or may not be directly associated with Xarelto's primary indications.
Patient Guidance: What This Payment Means for You
Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for educational purposes related to medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for educational purposes to specialists in Allergy & Immunology are not uncommon, but the specific drug and amount warrant consideration within industry norms.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharma-payments
- medical-education
- anticoagulants
- allergy-immunology
- regeneron-pharmaceuticals
- cms-open-payments
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $846.33 payment for?
This was a general payment of $846.33 from Regeneron Pharmaceuticals to Melissa Reed, categorized as "Education". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Melissa Reed accept pharmaceutical money?
Yes, Melissa Reed received this $846.33 payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Melissa Reed's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $846.33 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Allergy & Immunology?
To compare this payment against Allergy & Immunology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Allergy & Immunology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Melissa Reed's relationship with Regeneron Pharmaceuticals?
The payment amount is specific, suggesting a defined educational activity. This $846.33 general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Allergy & Immunology?
The date of payment falls on a major holiday, which is unusual for standard business transactions.
What should patients do after learning about this payment?
Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for educational purposes related to medications.
What else should I know about this general payment?
Xarelto is primarily an anticoagulant, and its connection to Allergy & Immunology requires further clarification.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.